What's Happening?
Susan Krumplitsch has joined Womble Bond Dickinson as a partner in its patent prosecution and litigation practice group in Silicon Valley. Krumplitsch brings extensive experience in representing clients across biotechnology, pharmaceutical, and medical
device sectors in patent and trade secret matters. Her practice includes cutting-edge technologies such as next-generation DNA sequencing and therapeutic monoclonal antibodies. Krumplitsch's move from DLA Piper to Womble Bond Dickinson is expected to enhance the firm's capabilities in handling complex patent litigation and prosecution.
Why It's Important?
Krumplitsch's addition to Womble Bond Dickinson strengthens the firm's presence in Silicon Valley, a hub for technological innovation and intellectual property disputes. Her expertise in biotechnology and pharmaceuticals aligns with the growing demand for legal services in these sectors, driven by advancements in medical research and development. The move reflects the competitive nature of the legal industry, where firms seek to attract top talent to bolster their service offerings and client base. Krumplitsch's experience in federal courts and the US Patent and Trademark Office positions the firm to effectively navigate the complexities of patent law.
